Physician profile
Mark L Hoff
NPI 1558455618
$33,750.08
in general payments reported to CMS, 2019-2025
75 companies · $4,459 in 2025
The $4,459 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,811 · 2020: $5,099 · 2021: $6,453 · 2022: $5,035 · 2023: $3,888 · 2024: $4,005 · 2025: $4,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,351.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,703.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $3,090.29 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $3,073.63 | 2019-2025 | |
| Amgen INC. | $2,579.74 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,114.86 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $2,069.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $1,396.31 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,179.44 | 2019-2025 | |
| Corcept Therapeutics | $1,143.14 | 2020-2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $1,107.88 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Novartis Pharmaceuticals Corporation | $982.15 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $942.56 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $819.54 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $727.12 | 2019-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $652.40 | 2020-2025 | Nexletol |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.